Workshop: Applying Exposure Science to Increase the Utility of Non-Animal Data in Efficacy and Safety Testing, 16 Feb. 2017
|
|
|
- Sybil Sherman
- 6 years ago
- Views:
Transcription
1 Workshop: Applying Exposure Science to Increase the Utility of Non-Animal Data in Efficacy and Safety Testing, 16 Feb. 2017
2 Presentation Outline Should we account for kinetics in vitro and in vivo for quantitative in vitro-in vivo extrapolation (QIVIVE) purposes? 0 QIVIVE 0 Toxicokinetis 0 Free concentration 0 Repeated Dosing
3 % affected people In Vitro Assays in Risk Assessment 0 Toxicity Testing in 21 st Century 0 National Research Council (2007), Toxicity Testing: A Vision and a Strategy, DOI: / From hazard identification to hazard characterization 0 Quantitative In Vitro-In Vivo Extrapolation (QIVIVE) 0 Estimating chemical exposures producing target tissue exposures in humans equivalent to those associated with effects in in vitro toxicity tests? ADI? Dose (mg/kg bw)
4 Louisse et al. (2010) Tox. Sci. 118: 470 QIVIVE In vitro toxicodynamics Mouse embryonic stem cell test Input: BMC values metabolite alkoxyacetic acid Blood Blood Fat Fat In vitro toxicokinetics Biotransformation kinetics in rat hepatocytes Rapidly perfused tissue Slowly perfused tissue Liver Rapidly perfused tissue Slowly perfused tissue Liver Evaluation of IVIVE model with in vivo embryotoxic doses alkoxyacetic acid formation GI tract Output: predicted oral embryotoxic dose parent glycol ethers
5 % of living cells In Vitro Assays 0 Toxicodynamics EC 50 0 Toxicokinetics concentration
6 Toxicokinetics Input Parameters Passive diffusion down C gradient J = P app *SA*C e.g. Caco-2, PAMPA Diffusion into tissue Non-saturable protein binding, fu Well-stirred tissue Whole-body D perfusion-limited e.g. RED, SPME Bessems et al. (2014) Reg. Toxicol. Pharmacol. 68, 119 Peyret and Krishnan (2011) SAR QSAR Environ. Res. 22, 129 Liao et al. (2007) Risk Anal. 27, 1223 Wetmore (2015) Toxicol. 332, 94 e.g. microsomes, cryopreserved hepatocytes e.g. RPTEC/TERT1
7 Dose Metrics in QIVIVE oral dose C plasma C tissue Hermens et al (2007) JTEH-A 70: 727 Kretschmann et al (2012) Env. Tox. Chem 31: 2014
8 Distribution of a chemical in vitro Differences between in vitro assays influencing the fraction of test chemical in cells: evaporation PLASTIC (well) protein binding plastic binding free in medium MEDIUM cell binding CELL metabolism target free free in in cell cell 0Serum concentration 0Cell concentration 0Well plate dimensions 0Open vs closed systems 0Exposure time 0pH 0Temperature 0Dosing regimen 03D matrix 0Metabolic capacity 0Transporter presence 0Monolayer vs 3D structure 0Transwell vs well plate Groothuis et al., 2015 Toxicol. 332: 30
9 Distribution of a chemical in vitro that determine free concentrations in culture medium Properties affecting affinity for in vitro constituents, including: K d /LogP/LogD7.4/ K OW H pk a Properties affecting reactivity, degradation, metabolism Groothuis et al. (2015) Toxicol. 332: 30
10 Serum Protein Binding 0 Surfactants 0 Relationships with standard phys. chem. properties do not apply 0 Benzalkonium chlorides (C6-C18) 0 Measured K MW using IAM column, TRANSIL 0 Measured PPB using Resolvosil BSA-7 column 0 RTgill-W1 basal cytotoxicity assay (Kramer et al., 2012, Chem. Res. Toxicol. 25:436-45) 0 10% FBS, 4 g/l BSA in medium Groothuis et al., manuscript in preparation
11 Serum Protein Binding 0 Hypothesis 0 CMB Narcosis ~100 mmol/kg lipid 0 EC50 basal cytotoxicity (mm) x K MW (L/kg lipid) = CMB (mmol/kg lipid) 0 PPB increases with increasing alkyl chain length 0 Discrepancy hypothesized & measured EC50 increases with increasing alkyl chain length 0 Hypothesized EC50 = measured nominal EC50 for C6, C8 BAC 0 Measured unbound EC50 = hypothesized EC50 for BAC-C6 to C14 Groothuis et al., manuscript in preparation
12 Plastic Binding 0 Serum/BSA free medium 0 Measured nominal EC50 = hypothesized EC50 for BAC-C6 to C10 0 Fraction sorbed to plastic increases with increasing alkyl chain length up to BAC-C12 0 Fraction sorbed to plastic decreases with increasing concentration (saturation) 0 Measured actual conc. after 48h EC50 = hypothesized EC50 for BAC-C6 to C12 0 Homogenous dissolution issues in protein free medium for BAC-C14-C18 Groothuis et al., manuscript in preparation
13 Partitioning to Cells 0 Extracted BAC from cells after 48h exposure 0 LCMS/MS analysis of cell extracts 0 Nominal EC50 varied 3 orders of magnitude between BAC-C6 and C18 0 EC50 based on cell concentrations varied <1 order of magnitude between BAC-C6 and C18 0 ~1 mmol/kg cell lipid = EC50 for BAC 0 Similar mechanism of toxicity Groothuis et al., manuscript in preparation
14 Partitioning to Cells in a Substrate Depletion Assay 0 Substrate depletion assay 0 HepaRG in 12-well plate exposed to 3 µm pyrene 0 Medium concentrations measured at 0, 0.5, 1, 2, 4, 8, 16h 0 Biphasic depletion with distribution and elimination phase 0 k distribution (0-2h) 1.93 h -1, k elimination (2-16h) 0.14 h -1 0 Concentrations in cells (3 nmol/well) and on plastic (0.4 nmol/well) peak at 2h Groothuis et al. manuscript in preparation See also Jones and Houston (2004) Drug Metab Dispos 32:
15 Partitioning to Cells in Repeated Dosing Assays 0 Objective 0 27 drugs, varying mechanism of action Improve predictivity in vitro assays for adverse effects drugs after repeated dosing 0 Long-lived in vitro organotypic cell systems RPTEC/TERT1 Primary hepatocytes HepaRG 2D & 3D cocultures primary brain cells 0 Integrated omics readouts 0 Daily dosing for 14 days 0 Translate in vitro PoD to daily oral dose transcriptomics, proteomics, metabolomics Dose-response, PBPK modeling Mueller et al. (2015) Toxicol. In Vitro 30: 4
16 0 Objective Predict-IV WP3 Biokinetics In Vitro 0 Assess how kinetics of drugs in vitro explains variations in effects between drugs, cell types and assay setup 0 Difference in metabolic competence, transporters, dosing regimen, attachment matrix 0 Method 0 Analytically measure drugs, metabolites over time 0 Cells, labware, attachment matrices, medium Kramer et al. (2015) Toxicol. In Vitro 30: 217
17 Accumulation in Cells 0 Dependent on 0 Chemical 0 Lipophilicity (amiodarone vs ibuprofen) 0 Metabolism/transporter affinity (cyclosporin vs adefovir) 0 Cell type 0 Metabolic competence (hepatocytes) 0 Transporters (RPTEC/TERT1) 0 Dose 0 Time Kramer et al. (2015) Toxicol. In Vitro 30: 217
18 Accumulation in Cells Bellwon et al. (2015) Toxicol. In Vitro 30: 166; Bellwon et al. (2015) Toxicol. In Vitro Toxicol In Vitro : 62; Wilmes et al. (2013) J Proteomics 79, 180
19 Conclusions 0 Uptake of chemical into cells varies across in vitro assays, chemicals, dosing regimens and exposure times 0 To quantify AOPs in vitro and define in vitro PODs for QIVIVE: 0 Distinguish between kinetic and dynamic processes in vitro, esp. for repeat-dosing assays 0 Determine cell-associated concentrations over time
20
21 Aknowledgements 0 The many not mentioned here specifically 0 Floris Groothuis, Steven Droge 0 Unilever 0 Bas Blaauboer, Joop Hermens 0 EU FP7 Predict-IV 0 EU FP6 AcuteTox
Dosing for Controlled Exposure (DoCE): Dosing strategies for characterising in vitro dose-responses with increased relevance for in vivo extrapolation
Dosing for Controlled Exposure (DoCE): Dosing strategies for characterising in vitro dose-responses with increased relevance for in vivo extrapolation Background Chemical safety assessments continue to
Cosmetics Europe LRSS Programme
Cosmetics Europe LRSS Programme 2016-20 Rob Taalman Objectives of CE Research To deliver tools & strategies for animal-free safety assessment Accurate Robust Efficient ultimately accepted by regulators
Progress and Future Directions in Integrated Systems Toxicology. Mary McBride Agilent Technologies
Progress and Future Directions in Integrated Systems Toxicology Mary McBride Agilent Technologies 1 Toxicity testing tools of the late 20 th century Patchwork approach to testing dates back to the 1930
The Long Range Science Strategy (LRSS) of Cosmetics Europe
The Long Range Science Strategy (LRSS) of Cosmetics Europe Repeated dose systemic toxicity 2016 Bas Blaauboer Aim of LRSS: Development of a strategy to determine safety of cosmetic ingredients and products
New Approaches to Chemical Risk Assessment
New Approaches to Chemical Risk Assessment Wednesday, 11 May, 13.30-15.00 IAFP s European Symposium on Food Safety 2016, Athens, Greece New Approaches in Chemical Risk Assessment Dr Ans Punt RIKILT Wageningen
Metabolite ID. Introduction
Metabolite ID Introduction Drug metabolism plays an increasingly important role in the drug discovery and development process. For the early discovery phase, investigating drug metabolism is intended to
The Role of Chemistry in Adverse Outcome Pathways. Paul Russell & Steve Gutsell Safety and Environmental Assurance Centre, Unilever April 2013
The Role of Chemistry in Adverse Outcome Pathways Paul Russell & Steve Gutsell Safety and Environmental Assurance Centre, Unilever April 2013 Contents Background Risk Assessment in FMCG industry Drivers
Mechanistic bioaccumulation model(s) for ionogenic organic substances in fish
LRI-ECO21 Mechanistic bioaccumulation model(s) for ionogenic organic substances in fish Cefic-LRI Annual workshop Brussels, Nov. 2015 Partner 1 Partner 2 Partner 3 Partner 4 Partner 5 Rationale ECO21 1.
Extrapolation of in vitro effects to in vivo embryotoxicity Basic requirements for prediction model development. Han van de Sandt, PhD
Extrapolation of in vitro effects to in vivo embryotoxicity Basic requirements for prediction model development Han van de Sandt, PhD TNO: Netherlands Organisation for Applied Scientific Research Established
Initially proposed chemical mixtures for in vivo BCF experiments (WP2)
Initially proposed chemical mixtures for in vivo BCF experiments (WP2) Mixture 1 (at 2 different ph s) Primary alkyl amine Secondary alkyl amine Tertiary alkylamine Quaternary alkylamine Mixture 2 Mixture
Moving Towards Version 2.0 of Toxicity Testing in the 21 st Century and Application to Regulatory Decision Making
Moving Towards Version 2.0 of Toxicity Testing in the 21 st Century and Application to Regulatory Decision Making ECHA Topical Scientific Workshop on New Approach Methodologies April 20, 2016 Rusty Thomas
The Dose: Toxicokinetics for Human Health Risk Assessment
The Dose: Toxicokinetics for Human Health Risk Assessment John C. Lipscomb, PhD, DABT, ATS U.S. Environmental Protection Agency Office of Research and Development National Center for Environmental Assessment
Current Guidelines for Drug-drug Interaction Evaluation
Current Guidelines for Drug-drug Interaction Evaluation Odette A Fahmi, PhD DDI-Edge Consulting, LLC June 2018 21 ST International Conference on Drug-Drug Interactions OUTLINE Recommended DDI approaches
drug discovery: Where are we now? How did we RSC February 2013
The role of pharmacokinetics in drug discovery: Where are we now? How did we get th here??where are we going? Peter Webborn RSC February 2013 Why conduct PK studies in animals? The primary purpose of pre-clinical
Lipoidal permeability central to drug ADME Major barriers to drug discovery: dogma surrounding plasma protein binding and tissue concentration
Lipoidal permeability central to drug ADME Major barriers to drug discovery: dogma surrounding plasma protein binding and tissue concentration Lipoidal permeability of typical antagonists / inhibitors
How discovery activities can influence metabolic profiling in the regulatory space? C. DELATOUR EBF, 25 th September 2015
How discovery activities can influence metabolic profiling in the regulatory space? C. DELATOUR EBF, 25 th September 2015 Outline 2 ן Background - Objectives - Shift in Workflow - Metabolite in safety
Current practice and future vision on metabolite profiling and quantification in Drug development
Current practice and future vision on metabolite profiling and quantification in Drug development Geert Mannens EBF Focus workshop Metabolite Profiling and Quantification Strategies in Drug R&D Sept 25,
SHORT COURSE DETAILS
SHORT COURSE DETAILS Short Course 3: In silico Modeling of in vitro Metabolism, Transport, and Toxicity Data Chair: Iain Gardner, Certara 13:30-13:45 Why is Modeling of in vitro Data Important? Iain Gardner,
Passive Dosing of hydrophobic organic chemicals (HOCs) to in vitro assays controlling, defining and linking exposure
Passive Dosing of hydrophobic organic chemicals (HOCs) to in vitro assays controlling, defining and linking exposure Philipp Mayer Contributions from Dorothea Gilbert, Stine Schmidt, Kilian Smith and more
Update of the WHO/IPCS Mode of Action Framework
Update of the WHO/IPCS Mode of Action Framework ECETOC/WHO/IPCS Mode of Action Workshop Vienna, February 21 st 22 nd, 2013 Presented by: M.E. (Bette) Meek University of Ottawa bmeek@uottawa.ca Outline
Progress in the Toxicity Testing in the 21 st Century (TT21C) Proposal
Progress in the Toxicity Testing in the 21 st Century (TT21C) Proposal AXLR8 Workshop 2011 Berlin-Dahlem, Germany May 24-26, 2011 Harvey Clewell Director, Center for Human Health Assessment The Hamner
Pharmacokinetics. Processes, Mathematics, and Applications. Second Edition. Peter G. Welling. Institut de Recherche Jouveinal
Pharmacokinetics Processes, Mathematics, and Applications Second Edition Peter G. Welling Institut de Recherche Jouveinal ACS Professional Reference Book American Chemical Society Washington, DC Contents
PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials. Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis
PK and PK/PD Guided Starting Dose Selection for First-In-Human Trials Sylvia Zhao ( 赵子微 ) Translational Clinical Oncology Novartis Disclaimer Contents are the opinion of the author and not that of Novartis
SEURAT-1: Why predictive safety science is important to regulatory acceptance of alternative methods
1 SEURAT-1: Why predictive safety science is important to regulatory acceptance of alternative methods Ian A Cotgreave Swedish Toxicology Sciences Research Center On behalf of all SEURAT-1 partners 10
PHYSIOLOGICALLY-BASED KINETIC MODELLING IN RISK ASSESSMENT REACHING A WHOLE NEW LEVEL IN REGULATORY DECISION-MAKING At a glance*
The European Commission s science and knowledge service Joint Research Centre PHYSIOLOGICALLY-BASED KINETIC MODELLING IN RISK ASSESSMENT REACHING A WHOLE NEW LEVEL IN REGULATORY DECISION-MAKING At a glance*
In vitro to in vivo extrapolation of hepatic metabolism in fish: an inter laboratory comparison of in vitro methods
ILSI Health and Environmental Sciences Institute In vitro to in vivo extrapolation of hepatic metabolism in fish: an inter laboratory comparison of in vitro methods Kellie Fay, USEPA HESI Annual Meeting
NEWSLETTERNEWSLETTERNEW
NEWSLETTERNEWSLETTERNEW ACuteTox April 2010 - Research Project for Alternative Testing CONTACT: CECILIA CLEMEDSON, DEPT. OF NEUROCHEM., STOCKHOLM UNIV., SE-10691 STOCKHOLM, SWEDEN, CECILIA.CLEMEDSON@NEUROCHEM.SU.SE
Value Scale (1-5) Summary of Results
In this example, the set of compounds that were studied satisfied many of the criteria for "drug likeness". However, in this program, there were issues with potency, novelty, and metabolic stability. This
Dr. M.Mothilal Assistant professor
Dr. M.Mothilal Assistant professor Complex picture of drug interactions in the body. This slide gives an idea of the complexity of drug disposition. Shown in this slide are many of the steps to getting
Introduction to Drug Development in Commercializing Biomedical Technology
Introduction to Drug Development in Commercializing Biomedical Technology Kevin W. Hunt, Ph.D. Director of Biopharmaceutical Product Development Office of Technology Development and Head of Translational
Applicability of the AOP for Assessing Causality of Observations in Epidemiological Studies
Applicability of the AOP for Assessing Causality of Observations in Epidemiological Studies Presented by: M.E. Meek, University of Ottawa bmeek@uottawa.ca 2 Outline Background on Adverse Outcome Pathways
High affinity target binding: a cause of non-linear Pharmacokinetics of drugs (Target mediated drug disposition: TMDD)
High affinity target binding: a cause of non-linear Pharmacokinetics of drugs (Target mediated drug disposition: TMDD) Devang Shah Senior Principal Investigator Metabolism and Pharmacokinetics, Pharmaceutical
Chagas Disease Drug Discovery Entering a New Era. Eric Chatelain, PhD Head of Drug Discovery
Chagas Disease Drug Discovery Entering a New Era Eric Chatelain, PhD Head of Drug Discovery ICOPA Meeting, Mexico, 12 th August 2014 Chagas Disease Effective immune responses provide control of the infection
Needs and Future Perspectives of Modelling Skin Permeability and Metabolism
Needs and Future Perspectives of Modelling Skin Permeability and Metabolism Mark Cronin School of Pharmacy and Chemistry Liverpool John Moores University England E-mail: m.t.cronin@ljmu.ac.uk Reasons for
Supporting information. Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo
Supporting information Single-cell and subcellular pharmacokinetic imaging allows insight into drug action in vivo Greg Thurber 1, Katy Yang 1, Thomas Reiner 1, Rainer Kohler 1, Peter Sorger 2, Tim Mitchison
2017 PROGRAM Hands-On Training
- FORMAT - - REGISTRATION FEE - 2 days training From Thursday morning to Friday evening 590 euros* without VAT Lectures Thursday morning Laboratory practices Rest of the time Training certificate can be
Cover Page. The handle holds various files of this Leiden University dissertation
Cover Page The handle http://hdl.handle.net/1887/30138 holds various files of this Leiden University dissertation Author: Driessen, Marja Title: Evaluation of the zebrafish embryo as an alternative model
Waters Solutions for DMPK and Biomarker Analysis. Waters User Meeting ASMS 2011 Denver, Colorado. Stephen McDonald
Waters Solutions for DMPK and Biomarker Analysis Waters User Meeting ASMS 2011 Denver, Colorado Stephen McDonald 2011 Waters Corporation 1 Drug Development Process Pre-clinical testing R&D - 18 months
Bioaccumulation Tests For Hydrophobic
ECO33: Use & Interpretation Of Dietary Bioaccumulation Tests For Hydrophobic Chemicals (2017-2018) Frank Gobas, Yung-Shan Lee and Justin Lo Simon Fraser University, Vancouver, British Columbia, Canada
Biological Sample Collection
Biological Sample Collection ~ Interstitial Fluids & Aqueous Humor ~ Chao-Cheng (Sam) Wang, PhD Department of Dermatology UAB Purdue-UAB Botanical Workshop, September 11-12, 2006 Targets for Biological
PBPK A Platform for Bridging People & Knowledge in Early Drug Development Club Phase I workshop PBPK: A new Paradigm in Drug Development Neil Miller
PBPK A Platform for Bridging People & Knowledge in Early Drug Development Club Phase I workshop PBPK: A new Paradigm in Drug Development Neil Miller 27 th April 2017 Summary Take home messages PBPK has
Developing a human chip based platform for repeated dose toxicity testing. Heike Walles Roland Lauster Gerd Lindner Uwe Marx
Developing a human chip based platform for repeated dose toxicity testing Heike Walles Roland Lauster Gerd Lindner Uwe Marx Repeated dose toxicity testing status quo Daily observation and sampling: hematology
INTRODUCTION PATRICK POULIN, 1,2 SAMI HADDAD 2
RESEARCH ARTICLE Pharmacokinetics, Pharmacodynamics and Drug Transport and Metabolism Albumin and Uptake of Drugs in Cells: Additional Validation Exercises of a Recently Published Equation that Quantifies
Comparative Assessment of In Vitro In Vivo Extrapolation Methods used for Predicting Hepatic Metabolic Clearance of Drugs
Comparative Assessment of In Vitro In Vivo Extrapolation Methods used for Predicting Hepatic Metabolic Clearance of Drugs PATRICK POULIN, 1 CORNELIS E. C. A. HOP, 2 QUYNH HO, 2 JASON S. HALLADAY, 2 SAMI
Fig. 4. A two-compartment pharmacokinetic model.
3.4 Pharmacokinetic (PK) modeling and simulations Noora Sjöstedt, Wilma Kiander, Heidi Kidron 3.4.1 Introduction (Hanna Kortejärvi) Pharmacokinetic modeling and simulations can be performed with different
Nanosize: What Can We Learn about Nonclinical Evaluations? Abby Jacobs CDER/FDA 1/2014 NOT official CDER/FDA policy
Nanosize: What Can We Learn about Nonclinical Evaluations? Abby Jacobs CDER/FDA 1/2014 NOT official CDER/FDA policy The Interplay Between Characterization and Toxicology (a) How do we know the material
Value Scale (1-5) 1 I. Final Product Profile Characteristics of the product required for patient care
In this example, the majority of the compounds was active in the xenograft model and showed "drug-like" properties from in-silico and experimental data. However, the animal studies showed moderate toxicity
Toxicokinetic models and their applications
Toxicokinetic models and their applications L. Zivkovic Toxicological Centre, Podgorica, Montenegro, lukazi@hdcg.co.me Abstract. In this paper toxicokinetics was examined. Chemical distribution, absorption
Oral Delivery of Drugs
Oral Delivery of Drugs 1 S E S S I O N O N E O F T I P P R O J E C T Advantages of taking oral drugs Convenient (storage, portability, premeasured dose) economical non-invasive, often safer route requires
Informatics and High Resolution QTof MS. How can we ask better questions and get better answers in DMPK? Mark D. Wrona
Informatics and High Resolution QTof MS How can we ask better questions and get better answers in DMPK? Mark D. Wrona Principal Scientist Pharmaceutical & Life Sciences, Waters Corporation Pacific Northwest
Information Sharing and Automation of PK Calculations for Efficient Project Support
Information Sharing and Automation of PK Calculations for Efficient Project Support Tibco Spotfire UM, Basel, Nov 3 rd, 2016 Stefanie Bendels Quantitative Systems Pharmacology Pharmaceutical Sciences,
Acceptance of New Technology. Richard Phillips, ExxonMobil Petroleum & Chemical CEFIC LRI 11th Annual Workshop, 19 November 2009
Acceptance of New Technology Richard Phillips, ExxonMobil Petroleum & Chemical CEFIC LRI 11th Annual Workshop, 19 November 2009 Overview Acceptance of New Technology Within LRI Nanotechnology New Approaches
Delivering in vitro DM assay services
Delivering in vitro DM assay services UGM_BIORAILS Copenhagen, 19-20 Oct 2017 Annalisa Pellacani An Integrated Approach to Drug Discovery: from Target to Clinic Target ID and Validation Screening and Hit
NMR in Drug Metabolism Extraction NMR - Keeping up with the Pace of Drug Discovery. Dr Ute Gerhard
F NMR in Drug Metabolism Extraction NMR - Keeping up with the Pace of Drug Discovery Dr Ute Gerhard The Early Days Eat plant Feel Worse Feel Better Try again Drug! The Golden Age Make molecule Feed to
CEFIC Long-range Research Initiative Request for Proposals (RfP)
Title and Code Number: Enhanced Screening Methods to Determine Bioaccumulation Potential of Chemicals in Air- Breathing Species LRI ECO41 Background The globally accepted model for bioaccumulation determination
Main achievements & Progress in Gianni Dal Negro, GlaxoSmithKline Industry Co-Chair EPAA Steering Committee
Main achievements & Progress in 2011 Gianni Dal Negro, GlaxoSmithKline Industry Co-Chair EPAA Steering Committee Overview of EPAA activities in 2011 Focus on Integrated Testing Strategies (annual theme)
Biology 137 Introduction to Toxicology Fall Which of the following would enhance the excretion of xenobiotic molecules?
1. Which of the following would enhance the excretion of xenobiotic molecules? A) removal of hydroxyl groups and replacement with hydrogen B) increased hydrophobicity of the molecule, which would allow
IN VITRO TOXICITY TESTING: TECHNOLOGIES AND GLOBAL MARKETS
IN VITRO TOXICITY TESTING: TECHNOLOGIES AND GLOBAL MARKETS PHM017E January 2014 Robert Hunter Project Analyst ISBN: 1-56965-661-4 BCC Research 49 Walnut Park, Building 2 Wellesley, MA 02481 USA 866-285-7215
Tox21: Opportunities& Challenges. Richard A. Becker Ph.D., DABT American Chemistry Council
Tox21: Opportunities& Challenges Richard A. Becker Ph.D., DABT American Chemistry Council October 21, 2010 Opportunities and Challenges The manifest challenge is to develop in vitro and in silico approaches
TIDES 2014 GalNAc-siRNA with Enhanced Stabilization Chemistry: ESC-GalNAc-siRNA. May 14, 2014 Muthiah Manoharan
TIDES 2014 GalNAc-siRNA with Enhanced Stabilization Chemistry: ESC-GalNAc-siRNA May 14, 2014 Muthiah Manoharan Agenda sirna-galnac Conjugates: Background Standard Template Chemistry (STC)» Human POC of
Tuzzy Talk # 6: Effects of Oil, Dispersants and Dispersed Oil on Organisms Part 1: Introduction to Toxicology
Tuzzy Talk # 6: Effects of Oil, Dispersants and Dispersed Oil on Organisms Part 1: Introduction to Toxicology Oct 4, 2014 Nancy E. Kinner University of New Hampshire Center for Spills in the Environment
Current practices on metabolite profiling and quantification in Drug Development at Boehringer-Ingelheim
Current practices on metabolite profiling and quantification in Drug Development at Boehringer-Ingelheim S Blech EBF Focus Workshop: Metabolite Profiling and Quantification Strategies in Drug R&D Sep 25,
DISCOVERY AND VALIDATION OF TARGETS AND BIOMARKERS BY MASS SPECTROMETRY-BASED PROTEOMICS. September, 2011
DISCOVERY AND VALIDATION OF TARGETS AND BIOMARKERS BY MASS SPECTROMETRY-BASED PROTEOMICS September, 2011 1 CAPRION PROTEOMICS Leading proteomics-based service provider - Biomarker and target discovery
Toxicity testing in the 21st Century: Challenges and Opportunities
Toxicity testing in the 21st Century: Challenges and Opportunities Alan R Boobis Imperial College London a.boobis@imperial.ac.uk 10 th CONCAWE Symposium 26 th February, 2013 Brussels, Belgium Risk assessment
New methods: miniorgans
New methods: miniorgans C. Rovida CAAT-Europe, University of Konstanz 16 maggio 2018 Parma Summer School 2018 Emerging Risks for Food Safety and Public Perception 1981 2010 www.ecopa.eu 2012 Stakeholder
The Challenges of Designing Cyclic Prodrugs of Opioid Peptides that Permeate the Intestinal Mucosa and the Blood-Brain Barrier
The Challenges of Designing Cyclic Prodrugs of pioid Peptides that Permeate the Intestinal Mucosa and the Blood-Brain Barrier Ronald T. Borchardt Department of Pharmaceutical Chemistry The University of
DETERMINATION OF PROTEIN BINDING BY UPLC/MS/MS
DETERMINATION OF PROTEIN BINDING BY UPLC/MS/MS Darcy Shave and Pete Alden Waters Corporation, Milford, MA, U.S.A. INTRODUCTION Plasma protein binding (PPB) can significantly affect the therapeutic action
Validation of the 21 st Century Toxicology Toolbox: Challenges, Opportunities, and the Way Forward
Validation of the 21 st Century Toxicology Toolbox: Challenges, Opportunities, and the Way Forward William S. Stokes 1, Judy Strickland 2, and Warren Casey 1 1 National Toxicology Program Interagency Center
Can Organ-on-a-Chip Technology Really Replace Animal Testing of Drug and Chemical Safety?
1 Can Organ-on-a-Chip Technology Really Replace Animal Testing of Drug and Chemical Safety? J Malcolm Wilkinson, CEO, Kirkstall Ltd. Quasi Vivo - saving lives through better science The drug development
Basic principles of the safety assessment of drugs
Basic principles of the safety assessment of drugs SFT Annual meeting 2013 Björn Dahl, PhD Senior Project Director Global Safety Assessment AstraZeneca R&D Outline of presentation Safety assessment in
Current Status: CPTR PBPK Modelling Effort. Lisa Almond Translational Science (DMPK) Simcyp Limited (a Certara Company)
Current Status: CPTR PBPK Modelling Effort Lisa Almond Translational Science (DMPK) Simcyp Limited (a Certara Company) lisa.almond@certara.com Project Objectives To develop an exploratory PBPK model for
TOXICITY STUDIES. Mr.D.Raju M.Pharm., Lecturer
TOXICITY STUDIES Mr.D.Raju M.Pharm., Lecturer INTRODUCTION A drug is a single substance or mixture of substances used for diagnosis, treatment, mitigation or prevention of disease ; restoring, correcting
Revidierte ICH M3 Auswirkungen auf die präklinische Arzneimittelentwicklung. Pharmakologie, ADME, Missbrauchs- Potential und Kombinations-Toxizität
Revidierte ICH M3 Auswirkungen auf die präklinische Arzneimittelentwicklung Pharmakologie, ADME, Missbrauchs- Potential und Kombinations-Toxizität PD Dr. Elke Röhrdanz Präklinik Fachgebiet Klinische Prüfung
Submission of comments on 'Concept paper on a revision of the Guideline on the investigation of drug interactions' (EMA/CHMP/694687/2016)
30 th June 2017 Submission of comments on 'Concept paper on a revision of the Guideline on the investigation of drug interactions' (EMA/CHMP/694687/2016) Comments from: Name of organisation or individual
Pharmacokinetics-pharmacodynamics analysis of spiroindolone analogs and KAE609 in. a murine malaria model
1 2 3 4 5 Pharmacokinetics-pharmacodynamics analysis of spiroindolone analogs and KAE609 in a murine malaria model Suresh B. Lakshminarayana 1#, Céline reymond 2,3, Christoph ischli 2,3, Jing Yu 4, Sebastian
Chancen und Limitationen von PK/PD Modellen
Chancen und Limitationen von PK/PD Modellen Stephan Schmidt, Ph.D. Center for Pharmacometrics and Systems Pharmacology (CPSP), University of Florida, Orlando, USA 23. Jahrestagung der Pau-Ehrlich-Gesellschaft
Hazard identification Dose-response assessment Exposure assessment Risk characterization In vivo animal experiments Endpoint assays (mortality) Epidemiological studies Environmental monitoring Extrapolation
Welcome to the American College of Toxicology s Webinar Series
Welcome to the American College of Toxicology s Webinar Series Thank You to Our Co-sponsors British Toxicology Society Society of Toxicologic Pathology Drug Metabolite(s) Safety Tes>ng Fred Alavi, Ph.D.
Aptamer-Functionalized Delivery System for Osteogenic sirnas to Achieve Osteoblast- Specific RNA Interference for Bone Anabolic Therapy
Aptamer-Functionalized Delivery System for Osteogenic sirnas to Achieve Osteoblast- Specific RNA Interference for Bone Anabolic Therapy Chao Liang 1,2, Baosheng Guo 1, Heng Wu 1, Lingqiang Zhang 2, Aiping
SUPPLEMENTARY INFORMATION
In format provided by Orchard et al. (SEPTEMBER 2011) Supplementary information S1 Sample MIABE file exemplifying data extracted from PMID: 20568778 Responsible Person or Role Contact Person Bryan K. S.
Applied Biosystems/MDS Sciex LC/MS Users Meeting Daiichi Pure Chemicals Co., Ltd.
Introduction ADMET screening Drug-drug interaction Introduction ADMET screening 40% ADMET screening in vitro Absorption : Caco-2 Permeability, Transporter assay Distribution : Protein binding, Transporter
Predicting Metabolites
Predicting Metabolites Enhancing An Expert System With Machine Learning Chris Barber Director f Science chris.barber@lhasalimited.org Boston, May 2015 Lhasa Limited: What We Do Lhasa Limited is a not-for-profit
Pre-Clinical Evaluation of ALN-AAT to Ameliorate Liver Disease Associated with Alpha-1 Antitrypsin Deficiency
Pre-Clinical Evaluation of ALN-AAT to Ameliorate Liver Disease Associated with Alpha-1 Antitrypsin Deficiency A. Sehgal 1, K. Blomenkamp 2, K Qian 1, A. Simon 1, P. Haslett, S. Barros 1, J. Teckman 2 May
Non-Animal Approaches - The Way Forward Multi-Organ-Chip developments: Towards a paradigm shift in drug development
Non-Animal Approaches - The Way Forward Multi-Organ-Chip developments: Towards a paradigm shift in drug development Transatlantic Think Tank on Toxicology Berlin June 2015 Biology-inspired microphysiological
INTRODUCTION TO PHARMACOLOGY
INTRODUCTION TO PHARMACOLOGY Pharmacology is the study of how chemicals interact with the body Endogenous hormones, growth factors, etc Exogenous drugs Two areas of study Pharmacodynamics Interaction of
Pharmacology. Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University.
Pharmacology Chatchai Chinpaisal, Ph.D. Department of Pharmacology and Toxicology, Faculty of Pharmacy, Silpakorn University. 1 PHARMACODYNAMIC STUDIES A. Primary pharmacodynamics primary action in target
! Background. ! What is really new?! The new Section 7: Explorative Clinical Trials (ECTs) ! Consequences in General
! Background! What is really new?! The new Section 7: Explorative Clinical Trials (ECTs)! 5 Approaches (Table 3) for:! Microdose trials (7.1)! Single-Dose (SD) Trials at Sub-therapeutic Doses or Into the
Human Vss Prediction. James Yates AstraZeneca. Disclaimer 10/25/2011
0/25/20 Human Vss Prediction Part 2: Comparative Assessment of Prediction Methods of Human Volume of Distribution R.D.O JONES,H.M. JONES, M. ROWLAND, C.R. GIBSON, J.W.T. YATES, J.Y. CHIEN, B. J. RING,
Subcommittee on Distinguishing Adverse from Non-Adverse and Adaptive Effects
Subcommittee on Distinguishing Adverse from Non-Adverse and Adaptive Effects DOUGLAS A. KELLER, PhD (sanofi-aventis US) Subcommittee Co-Chair HESI Annual Meeting Reston, VA May 13, 2010 1 The issue Advances
From Discovery to Development of new Drugs. and pitfalls along the way. by Kim Dekermendjian, PhD in Medicine BD & Key Account manager
From Discovery to Development of new Drugs. and pitfalls along the way by Kim Dekermendjian, PhD in Medicine BD & Key Account manager The roots of Drug Discovery Before 20 th century the term didn't exists,
Evolving approaches to AOP development: observations from MOA frameworks to systems biology
Evolving approaches to AOP development: observations from MOA frameworks to systems biology Molecular ini'a'ng event Intermediary steps Adverse Outcome Catherine WilleI, PhD Director, Regulatory Tes'ng
Hepatic ADME-Tox Products & Research Services
Hepatic ADME-Tox Products & Research Services Portfolio of Products & Services to Advance Research ACCELERATE R&D ǀ GAIN REGULATORY APPROVAL ǀ ACHIEVE COMMERCIAL OBJECTIVES BioIVT is the leading provider
INTRODUCTION PATRICK POULIN. Consultant, Québec city, Québec, Canada
RESEARCH ARTICLE Pharmacokinetics, Pharmacodynamics and Drug Transport and Metabolism A Paradigm Shift in Pharmacokinetic Pharmacodynamic (PKPD) Modeling: Rule of Thumb for Estimating Free Drug Level in
European Medicines Agency Evaluation of Medicines for Human Use COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT
European Medicines Agency Evaluation of Medicines for Human Use London, 27 July 2005 EMEA/CHMP/89249/2004 COMMITTEE FOR MEDICINAL PRODUCTS FOR HUMAN USE (CHMP) DRAFT Guideline on the Clinical Investigation
Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y. Report Price Publication date
F o r a c l e a r e r m a r k e t p e r s p e c t i v e Early Stage Drug Safety Strategies & Risk Management Maximizing opportunities towards achieving clinical success D R U G D I S C O V E R Y Report
The Use of Exposure Reconstruction to Link Exposure, Internal Dose, and Health Outcomes
The Use of Exposure Reconstruction to Link Exposure, Internal Dose, and Health Outcomes Harvey Clewell Director, Center for Human Health Assessment CIIT Centers for Health Research Research Triangle Park,
HARMONIZATION TEAM A6 (STABILITY) UPDATE. Yoshiaki Ohtsu 8 March 2012
HARMONIZATION TEAM A6 (STABILITY) UPDATE Yoshiaki Ohtsu 8 March 2012 Contents 1. General update 2. Scientific discussion point 1. Stability of presence of co administered or co formulated drugs 2. Incurred
Update on DDI Guidance of the FDA - In Vitro
Update on DDI Guidance of the FDA - In Vitro Xinning Yang, Ph.D. Policy lead Guidance & Policy Team (GPT) Office of Clinical Pharmacology (OCP) Office of Translational Sciences (OTS) Center for Drug Evaluation
FORMULATING FOR MICRONEEDLE DELIVERY. Professor Finn Bauer
FORMULATING FOR MICRONEEDLE DELIVERY Professor Finn Bauer OVERVIEW Conventional microneedle strategies Change of mind set to consider systemic delivery of therapeutic agents Design & manufacture considerations
Overzicht voortgang discussiepunten. Eric Verbruggen
Overzicht voortgang discussiepunten Eric Verbruggen Discussion points 19-03-2015 Contents 1. Introduction 2. Compartment 3. Persistence 4. Bioaccumulation Discussion Points 19-03-2015 Timeline of EU PBT